rais pt
post updat slide last week plan merger
nr upjohn busi manag compani met
investor address common question receiv deal sinc
stock vs suggest market
get comfort strateg financi aspect
combin concern china headwind management/
board/govern may persist continu see potenti
signific upsid newco rais pt maintain
color china headwind
headwind expect reduc upjohn revenu
compani quantifi lyrica loe impact
expans volume-bas procur vbp china
headwind primarili celebrex loe japan compani
expect total china sale includ lipitor
norvasc impact vbp viagra self-pay
sever product could impact
sale headwind primarili reflect step-down lipitor norvasc
lower sale product vbp expand
strategi roadmap newco
respons question newco busi execut capit alloc
provid roadmap slide highlight timelin integr cost
synergi realiz product launch contribut de-lever
prioriti discuss previous ad
expect power revenu synergi realiz start two year post-
close manag plan add metric roadmap complet
deal encourag potenti revenu synergi result
combin dial point
experi investor tend take well believ see view
forma analysi support upsid manag execut
refer previous publish pro forma analysi myl/upjohn
merger suggest potenti materi upsid sharehold
compani execut plan meet financi target particularli
newco valu higher multipl vs stand-alone appli
current ebitda multipl base case ebitda yield
theoret valu multipl would yield theoret valu
tr target
respect addit dcf analysi newco includ lower higher
sale scenario yield much higher theoret valu pleas see page prior note
detail
increas pt base newco ebitda
publish estim continu reflect stand-alone adjust price target
base pro forma model pt assum stock trade pro
forma ebitda similar myl current multipl ebitda theoret valu
base dcf analysi wacc termin growth rate order reflect current
risk-avers environ compani exposur us gener opioid and/or collus litig
high leverag compani continu deliv target see potenti
page
preliminari pro forma analysi upjohn
conduct pro forma analysi plan upjohn/mylan merger explor financi
implic deal compani expect close merger model full-
year impact start simplic manag provid financi project full-
year basi newco model base follow assumpt
estim reflect sale ramp driven new product consist
compani expect slight growth driven continu growth europ
row offset declin north america rel stabl sale
upjohn model revenu declin driven primarili
lyrica gener eros lyrica us sale repres upjohn revenu expans
volume-bas procur vbp china follow rel stabl sale assum
growth emerg market offset declin develop market
newco revenu midpoint compani target rang
includ manag expect upjohn
provid specif assumpt upjohn gross margin oper expens
underli ebitda target model oper expens similar
expens annual gross margin reflect eros
level prior lyrica gener eros
synergi manag target least
cost synergi year equat expens estim compani
forma tax rate similar myl
stand-alone tax rate higher end anticip
tax rate us-domicil global pharma compani figur
debt financ interest rate
assum newco issu debt favor term rel
stand-alone myl weighted-averag cost debt
figur summar base case estim newco model flattish revenu growth beyond
low single-digit ebitda growth driven primarili cost synergi note base case
reflect conserv outlook rel manag expect modest revenu growth
near term moder growth longer term compani anticip new
product launch revenu note analysi preliminari subject chang
learn
page
higher lower growth scenario
next consid variou scenario includ higher growth case newco revenu growth
vs growth base case lower growth case newco revenu growth
also model higher lower growth scenario conserv start point
revenu rel compani preliminari forecast reflect potenti
greater pressur expans volume-bas procur program china impact upjohn
sale lower pipelin contribut higher competit intens factor scenario
summar figur
page
figur upjohn/mylan pro forma scenario revenu guidanc
higher revenu growth
lower revenu growth
figur upjohn/mylan pro forma scenario revenu guidanc
revenu growth
revenu revenu growth
revenu revenu growth
page
theoret valu base ebitda multipl
current trade ebitda appli multipl ebitda
newco would yield theoret valu base case revenu downsid
scenario figur rel stand-alone newco divers revenu base term
product geographi includ reduc exposur challeng us gener market
stronger balanc sheet robust cash flow support grow dividend capit
deploy prioriti margin expans driven cost synergi potenti revenu growth
potenti revenu synergi contempl compani deal model could earn
newco higher multipl rel stand-alone hand newco could less growthi
rel stand-alone given larger revenu base import pipelin primari
growth driver appli multipl base case ebitda would yield theoret valu
multipl would yield
figur theoret valu base ebitda multipl
revenu guidanc
multipl pf ebitda
revenu guidanc
multipl pf ebitda
theoret valu base dcf analysi
also conduct dcf analysi scenario model sale period
calcul termin valu use termin growth rate discount after-tax profit back
end use estim wacc newco calcul wacc use myl beta
estim capit structur newco analysi yield theoret valu
base case higher growth case lower growth case figur theoret
dcf valu lower revenu downsid scenario
figur theoret valu base dcf analysi
revenu guidanc
base case growth
revenu growth
revenu growth
revenu guidanc
growth
revenu growth
revenu growth
page
interest
revenu
page
interest
revenu
page
rest world
rest world
revenu
rest world
page
rest world
rest world
revenu
rest world
page
develop manufactur market gener brand gener biosimilar brand
drug over-the-counter product countri myl north america busi primarili focus
gener drug europ row segment focus brand over-the-counter product
compani establish broad biosimilar portfolio collabor biocon
partner expect complet merger off-pat brand gener busi
upjohn
start point see stock depress valuat financi expect
lower enough believ stock outperform despit
challeng environ base divers global busi larg pipelin includ biosimilar
preliminari analysi plan upjohn/mylan merger suggest potenti signific
upsid sharehold compani execut plan meet financi target
particularli newco valu higher multipl rel stand-alone rate share buy
valuat risk
pt assum stock trade pro forma ebitda similar
current multipl ebitda theoret valu base dcf
analysi wacc termin growth rate order reflect current risk-avers environ
compani exposur us gener opioid and/or collus litig high leverag
risk rate price target includ failur complet merger upjohn increas
competit intens gener greater price pressur us europ area delay
approv quality/manufactur issu liabil relat opioid litig gener collus case
disappoint capit deploy
compani mention note
gregg gilbert herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
